<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677829</url>
  </required_header>
  <id_info>
    <org_study_id>PNT001-002</org_study_id>
    <nct_id>NCT04677829</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)</brief_title>
  <official_title>Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous PNT001 in Hospitalized Patients With Traumatic Brain Injury (TBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pinteon Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Pinteon Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multi-center, randomized, double-blind, placebo-controlled,&#xD;
      multiple-ascending- dose trial to evaluate the safety, tolerability, immunogenicity, and&#xD;
      pharmacokinetics of intravenous PNT001 in hospitalized patients with traumatic brain injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1 study is a double-blind, multiple ascending dose trial evaluating a total of 64&#xD;
      patients across two dose cohort groups. Each cohort will include 32 patients (24 active; 8&#xD;
      placebo) who will be randomized to receive three doses of either PNT001 or placebo. Doses&#xD;
      studied will be 1000mg and 4000mg.&#xD;
&#xD;
      Patients admitted to the trauma center who meet entrance criteria will receive their first&#xD;
      dose of study drug within 24 hours of documented TBI. They will remain in the facility for at&#xD;
      least 24 hours after initial dose. Baseline biomarker collection and cognitive assessments&#xD;
      will be completed. Study medication will be administered as an IV infusion over 30 minutes&#xD;
      (for 1000mg cohort) or 60 minutes (for 4000mg cohort) followed by collection of safety,&#xD;
      tolerability, pharmacokinetic, biomarker, imaging, and cognitive data over 12 weeks.&#xD;
      Subsequent dosing visits will be at Days 28 and 56. All visits after initial discharge will&#xD;
      be on an outpatient basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Escalating dose level cohorts; each cohort with an active and a placebo arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study drug will be administered and assessed in double-blinded fashion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>84 day study duration</time_frame>
    <description>assess adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Clinical Laboratory Test Abnormalities</measure>
    <time_frame>84 day study duration</time_frame>
    <description>measure clinical laboratory values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Abnormalities in Physical Examination Findings</measure>
    <time_frame>84 day study duration</time_frame>
    <description>perform physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Abnormalities in Neurological Examination Findings</measure>
    <time_frame>84 day study duration</time_frame>
    <description>perform neurological examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Abnormalities in Vital Signs</measure>
    <time_frame>84 day study duration</time_frame>
    <description>assess blood pressure, pulse, temperature, respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Abnormalities in 12-lead Electrocardiogram Assessment</measure>
    <time_frame>84 day duration of study</time_frame>
    <description>measure ECG parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Properties of PNT001 in Serum</measure>
    <time_frame>84 day duration of study</time_frame>
    <description>measure concentration of PNT001 in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-Drug Antibodies (ADA)</measure>
    <time_frame>84 day duration of study</time_frame>
    <description>number of participants with presence of anti-drug antibodies (ADA) in serum</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker Measurements in Plasma</measure>
    <time_frame>84 day duration of study</time_frame>
    <description>measure concentrations of total (mid-domain) tau, NfL, GFAP, UCH-L1, pT181 tau, pT231 tau total tau in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of PNT001 on imaging parameters</measure>
    <time_frame>Day 3 through the remainder of the 84 day study</time_frame>
    <description>measure diffusion tensor imaging parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of PNT001 on cognitive measures</measure>
    <time_frame>84 day duration of study</time_frame>
    <description>scores on the Trails A and B assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of PNT001 on health related Quality of Life</measure>
    <time_frame>84 day duration of the study</time_frame>
    <description>measure change in ratings across 8 categories on the NeuroQOL assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of PNT001 on a Global Outcome Scale</measure>
    <time_frame>84 day duration of the study</time_frame>
    <description>measure disability outcome based on ratings in 8 areas of the Global Outcome Scale Extended (GOSE)</description>
  </other_outcome>
  <other_outcome>
    <measure>hsCRP Measurement in Serum</measure>
    <time_frame>84 day duration of the study</time_frame>
    <description>measure concentrations of hsCRP in serum</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>PNT001 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PNT001 diluted in 5% dextrose for infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNT001 4000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PNT001 diluted in 5% dextrose for infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNT001</intervention_name>
    <description>30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg</description>
    <arm_group_label>PNT001 1000mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>%5 dextrose for infusion</intervention_name>
    <description>30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg</description>
    <arm_group_label>PNT001 4000mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalization due to documented evidence of TBI with Glasgow Coma Scale (GCS) Score&#xD;
             9-12 or GCS score of 13-15 with radiographic evidence of trauma.&#xD;
&#xD;
          2. Duration from documented time of TBI event to time of start of initial dose of study&#xD;
             drug will not exceed 24 hours.&#xD;
&#xD;
          3. Signed informed consent by patient, or where applicable, patient's legally authorized&#xD;
             representative.&#xD;
&#xD;
          4. Male and females, 18- 65 years of age at time of screening (State's legal age of&#xD;
             majority is minimum age if higher than 18).&#xD;
&#xD;
          5. Female patients must meet protocol defined criteria for 1) non-childbearing potential,&#xD;
             2) post menopausal or 3) must have a negative pregnancy test and agree to&#xD;
             contraception as outlined in the protocol.&#xD;
&#xD;
          6. Male must agree to use acceptable contraception and refrain from sperm donation during&#xD;
             the entire study and for 200 days after dosing has been completed.&#xD;
&#xD;
          7. Has not participated in a clinical drug trial within 3 months of study start.&#xD;
&#xD;
          8. Body Mass Index (BMI) of 18.5-35.0 kg/m2 and for the 4000mg dose group only, weight&#xD;
             greater than or equal to 44.8 kg.&#xD;
&#xD;
          9. Vision, hearing, speech, motor function, and comprehension sufficient for compliance&#xD;
             with all testing procedures and assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. TBI that does not require hospitalization.&#xD;
&#xD;
          2. TBI outside 24-hour window.&#xD;
&#xD;
          3. GCS &lt; 9 within 2 hours of dosing.&#xD;
&#xD;
          4. History of TBI in past 12 months that resulted in patient seeking medical attention.&#xD;
&#xD;
          5. Evidence of penetrating head trauma or depressed skull fracture.&#xD;
&#xD;
          6. Clinical or radiographic evidence of mass effect, midline shift, or intracranial&#xD;
             hypertension, requiring craniotomy/craniectomy.&#xD;
&#xD;
          7. Evidence of symptomatic cervical, thoracic, lumbar spine injury e.g. paresis,&#xD;
             radiculopathy, that can be localized to the injury.&#xD;
&#xD;
          8. Systemic traumatic injury that would preclude participation in study or is expected to&#xD;
             result in long-term disability.&#xD;
&#xD;
          9. Any other acute or chronic medical illness that in the judgement of the study&#xD;
             physician results in functional impairment or impairs neuropsychiatric function.&#xD;
&#xD;
         10. Any acute intoxication that in the judgement of the study physician results in&#xD;
             significant functional impairment or impairs neuropsychiatric function.&#xD;
&#xD;
         11. Any history of cancer within 5 years of enrollment with the exception of resected skin&#xD;
             basal cell carcinoma.&#xD;
&#xD;
         12. Any major surgery requiring general anesthesia within 4 weeks of study drug&#xD;
             administration.&#xD;
&#xD;
         13. Donation of blood or serum â‰¥500 mL to a blood bank or in a clinical study (except&#xD;
             screening visit) within 3 months of study drug administration.&#xD;
&#xD;
         14. Known recent (within 6 months of study drug administration) drug or alcohol abuse as&#xD;
             defined in DSM V, Diagnostic Criteria for Drug and Alcohol Abuse.&#xD;
&#xD;
         15. Evidence of any clinically significant neurological or psychiatric disorder that could&#xD;
             interfere with study assessments as determined by investigator and sponsor.&#xD;
&#xD;
         16. Patient has history or currently has schizophrenia, schizoaffective disorder or&#xD;
             bipolar disorder, untreated major depression (DSM-V or ICD-10 criteria).&#xD;
&#xD;
         17. Significant illness within the prior 30 days.&#xD;
&#xD;
         18. Abnormalities in creatinine, hepatic transaminases, or QT that would preclude entry&#xD;
             into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Altstiel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pinteon Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Luca, MSN</last_name>
    <phone>860-319-9938</phone>
    <email>wluca@pinteon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramon Diaz-Arrastia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

